← Leaderboards
David Zagzag
New York University School Of Medicine
$2,996,633
Attributed
$3,159,564
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $325.9K · FY2005–22$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,159,564 · 5
By mechanism
R01$1,676,426 · 2
R21$1,483,138 · 3
Top collaborators
- Matthias Angelos Karajannis1 shared
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularTumorAngiogenesisGliomaIn VivoNeoplastic CellBrain NeoplasmsBiologicalInvadedCellsBrainTumor Cell InvasionAnimal ModelHypoxia Inducible Factor 1Vascular Endothelial Growth FactorsResearch StudyAntibodiesMalignant - DescriptorBaseInhibitor/AntagonistGrowthAngiogenesis InhibitorsHarvestImmunohistochemistry
Grant awards (13)
Identification and molecular characterization of FGFR4 p.G388R variant signaling in cerebellar hemangioblastomas$232,969
R21 · FY2022 · CA · contact PI
Identification and molecular characterization of FGFR4 p.G388R variant signaling in cerebellar hemangioblastomas$198,103
R21 · FY2021 · CA · contact PI
Exploration of Activity of RAD001 in vivo in Vestibular Schwannomas and Meningiom$325,863
R01 · FY2017 · CA · contact PI
Novel CXCR4 Therapeutics to Block Bevacizumab-Induced Glioma Dissemination$105,625
R21 · FY2013 · NS · contact PI
Novel CXCR4 Therapeutics to Block Bevacizumab-Induced Glioma Dissemination.$211,250
R21 · FY2012 · NS · contact PI
Novel CXCR4 Therapeutics to Block Bevacizumab-Induced Glioma Dissemination.$253,500
R21 · FY2011 · NS · contact PI
Intranasal Drug Delivery to Inhibit Glioma Angiogenesis and Invasion$216,338
R21 · FY2010 · NS · contact PI
Intranasal Drug Delivery to Inhibit Glioma Angiogenesis and Invasion$265,353
R21 · FY2009 · NS · contact PI
Invasion and Angiogenesis in Malignant Gliomas$262,798
R01 · FY2008 · CA · contact PI
Invasion and Angiogenesis in Malignant Gliomas$262,798
R01 · FY2007 · CA · contact PI
Invasion and Angiogenesis in Malignant Gliomas$270,647
R01 · FY2006 · CA · contact PI
Invasion and Angiogenesis in Malignant Gliomas$277,160
R01 · FY2005 · CA
Invasion and Angiogenesis in Malignant Gliomas$277,160
R01 · FY2004 · CA